Ciro Celsa
@cirocelsa.bsky.social
Gastroenterologist and Hepatologist
Assistant Professor (RTDB) in Gastroenterology, University of Palermo, Italy
Research Fellow in Oncology, Imperial College, London, UK
Pianist
Assistant Professor (RTDB) in Gastroenterology, University of Palermo, Italy
Research Fellow in Oncology, Imperial College, London, UK
Pianist
Reposted by Ciro Celsa
Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma
The treatment landscape for unresectable hepatocellular carcinoma has undergone profound change over the past 5 years, presenting both unprecedented opportunities and complex decision-making challenge...
dailynews.ascopubs.org
November 14, 2025 at 3:19 PM
Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
📣Now online our new study on #GLP1RA and liver outcomes!🔬
GLP-1 agonists reduce risk of major liver events in T2 diabetes pts.
Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social
doi.org/10.1136/gutj...
GLP-1 agonists reduce risk of major liver events in T2 diabetes pts.
Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social
doi.org/10.1136/gutj...
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liv...
doi.org
March 1, 2025 at 12:50 PM
📣Now online our new study on #GLP1RA and liver outcomes!🔬
GLP-1 agonists reduce risk of major liver events in T2 diabetes pts.
Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social
doi.org/10.1136/gutj...
GLP-1 agonists reduce risk of major liver events in T2 diabetes pts.
Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social
doi.org/10.1136/gutj...
In press on @amergastroassn.bsky.social journal CGH
our multicenter study on 293 pts with PBC from Italy/UK
🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe.
👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria
www.cghjournal.org/article/S154...
our multicenter study on 293 pts with PBC from Italy/UK
🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe.
👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria
www.cghjournal.org/article/S154...
January 18, 2025 at 11:05 AM
In press on @amergastroassn.bsky.social journal CGH
our multicenter study on 293 pts with PBC from Italy/UK
🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe.
👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria
www.cghjournal.org/article/S154...
our multicenter study on 293 pts with PBC from Italy/UK
🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe.
👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria
www.cghjournal.org/article/S154...
Reposted by Ciro Celsa
OUR TEAM WON
Proud mama over here
Proud mama over here
December 7, 2024 at 3:53 PM
OUR TEAM WON
Proud mama over here
Proud mama over here